Histone Modifications and Their Targeting in Lymphoid Malignancies
In a wide range of lymphoid neoplasms, the process of malignant transformation is associated with somatic mutations in B cells that affect the epigenetic machinery. Consequential alterations in histone modifications contribute to disease-specific changes in the transcriptional program. Affected gene...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2021-12, Vol.23 (1), p.253 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 253 |
| container_title | International journal of molecular sciences |
| container_volume | 23 |
| creator | Fernández-Serrano, Miranda Winkler, René Santos, Juliana C Le Pannérer, Marguerite-Marie Buschbeck, Marcus Roué, Gaël |
| description | In a wide range of lymphoid neoplasms, the process of malignant transformation is associated with somatic mutations in B cells that affect the epigenetic machinery. Consequential alterations in histone modifications contribute to disease-specific changes in the transcriptional program. Affected genes commonly play important roles in cell cycle regulation, apoptosis-inducing signal transduction, and DNA damage response, thus facilitating the emergence of malignant traits that impair immune surveillance and favor the emergence of different B-cell lymphoma subtypes. In the last two decades, the field has made a major effort to develop therapies that target these epigenetic alterations. In this review, we discuss which epigenetic alterations occur in B-cell non-Hodgkin lymphoma. Furthermore, we aim to present in a close to comprehensive manner the current state-of-the-art in the preclinical and clinical development of epigenetic drugs. We focus on therapeutic strategies interfering with histone methylation and acetylation as these are most advanced in being deployed from the bench-to-bedside and have the greatest potential to improve the prognosis of lymphoma patients. |
| doi_str_mv | 10.3390/ijms23010253 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8745418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2618239243</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-e7c38c7dfaf987934e8c528bafc3a892bbec4171dd0e0de305b6c6d8c0ee1f6e3</originalsourceid><addsrcrecordid>eNpd0ctLAzEQBvAgiq2Pm2dZ8OLB6iTZR_YiaPEFFS_1HLLJbJuym9RkK_S_d7Uq1dME5sdHho-QEwqXnJdwZRdtZBwosIzvkCFNGRsB5MXu1ntADmJcADDOsnKfDHgGIHIBQ3L7aGPnHSbP3tjaatVZ72KinEmmc7Qhmaoww866WWJdMlm3y7m3JnlWjZ055bTFeET2atVEPP6eh-T1_m46fhxNXh6exjeTkU4p60ZYaC50YWpVl6IoeYpCZ0xUqtZciZJVFfawoMYAgkEOWZXr3AgNiLTOkR-S603uclW1aDS6LqhGLoNtVVhLr6z8u3F2Lmf-XYoizVIq-oDz74Dg31YYO9naqLFplEO_ipLlVJSQpynt6dk_uvCr4PrzvhTjJUt5ry42SgcfY8D69zMU5Gc5crucnp9uH_CLf9rgH6GKi_Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2618239243</pqid></control><display><type>article</type><title>Histone Modifications and Their Targeting in Lymphoid Malignancies</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Fernández-Serrano, Miranda ; Winkler, René ; Santos, Juliana C ; Le Pannérer, Marguerite-Marie ; Buschbeck, Marcus ; Roué, Gaël</creator><creatorcontrib>Fernández-Serrano, Miranda ; Winkler, René ; Santos, Juliana C ; Le Pannérer, Marguerite-Marie ; Buschbeck, Marcus ; Roué, Gaël</creatorcontrib><description>In a wide range of lymphoid neoplasms, the process of malignant transformation is associated with somatic mutations in B cells that affect the epigenetic machinery. Consequential alterations in histone modifications contribute to disease-specific changes in the transcriptional program. Affected genes commonly play important roles in cell cycle regulation, apoptosis-inducing signal transduction, and DNA damage response, thus facilitating the emergence of malignant traits that impair immune surveillance and favor the emergence of different B-cell lymphoma subtypes. In the last two decades, the field has made a major effort to develop therapies that target these epigenetic alterations. In this review, we discuss which epigenetic alterations occur in B-cell non-Hodgkin lymphoma. Furthermore, we aim to present in a close to comprehensive manner the current state-of-the-art in the preclinical and clinical development of epigenetic drugs. We focus on therapeutic strategies interfering with histone methylation and acetylation as these are most advanced in being deployed from the bench-to-bedside and have the greatest potential to improve the prognosis of lymphoma patients.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms23010253</identifier><identifier>PMID: 35008680</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Acetylation ; Apoptosis ; B-cell lymphoma ; Cell cycle ; Chemotherapy ; Clinical Trials as Topic ; DNA damage ; DNA methylation ; Drug development ; Enzymes ; Epigenesis, Genetic ; Epigenetics ; Gene expression ; Histones ; Histones - metabolism ; Humans ; Immune system ; Immunosuppressive agents ; Immunosurveillance ; Lymphatic system ; Lymphocytes B ; Lymphoma ; Lymphoma - genetics ; Lymphoma - metabolism ; Medical prognosis ; Models, Biological ; Mutation ; Neoplasms ; Protein Processing, Post-Translational ; Proteins ; Radiation therapy ; Review ; Signal transduction ; Transcription ; Tumors</subject><ispartof>International journal of molecular sciences, 2021-12, Vol.23 (1), p.253</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-e7c38c7dfaf987934e8c528bafc3a892bbec4171dd0e0de305b6c6d8c0ee1f6e3</citedby><cites>FETCH-LOGICAL-c412t-e7c38c7dfaf987934e8c528bafc3a892bbec4171dd0e0de305b6c6d8c0ee1f6e3</cites><orcidid>0000-0003-0245-2257 ; 0000-0002-5779-8805 ; 0000-0001-9040-8496 ; 0000-0002-7570-0242 ; 0000-0003-4148-9570 ; 0000-0002-3218-4567</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745418/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745418/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35008680$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fernández-Serrano, Miranda</creatorcontrib><creatorcontrib>Winkler, René</creatorcontrib><creatorcontrib>Santos, Juliana C</creatorcontrib><creatorcontrib>Le Pannérer, Marguerite-Marie</creatorcontrib><creatorcontrib>Buschbeck, Marcus</creatorcontrib><creatorcontrib>Roué, Gaël</creatorcontrib><title>Histone Modifications and Their Targeting in Lymphoid Malignancies</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>In a wide range of lymphoid neoplasms, the process of malignant transformation is associated with somatic mutations in B cells that affect the epigenetic machinery. Consequential alterations in histone modifications contribute to disease-specific changes in the transcriptional program. Affected genes commonly play important roles in cell cycle regulation, apoptosis-inducing signal transduction, and DNA damage response, thus facilitating the emergence of malignant traits that impair immune surveillance and favor the emergence of different B-cell lymphoma subtypes. In the last two decades, the field has made a major effort to develop therapies that target these epigenetic alterations. In this review, we discuss which epigenetic alterations occur in B-cell non-Hodgkin lymphoma. Furthermore, we aim to present in a close to comprehensive manner the current state-of-the-art in the preclinical and clinical development of epigenetic drugs. We focus on therapeutic strategies interfering with histone methylation and acetylation as these are most advanced in being deployed from the bench-to-bedside and have the greatest potential to improve the prognosis of lymphoma patients.</description><subject>Acetylation</subject><subject>Apoptosis</subject><subject>B-cell lymphoma</subject><subject>Cell cycle</subject><subject>Chemotherapy</subject><subject>Clinical Trials as Topic</subject><subject>DNA damage</subject><subject>DNA methylation</subject><subject>Drug development</subject><subject>Enzymes</subject><subject>Epigenesis, Genetic</subject><subject>Epigenetics</subject><subject>Gene expression</subject><subject>Histones</subject><subject>Histones - metabolism</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immunosuppressive agents</subject><subject>Immunosurveillance</subject><subject>Lymphatic system</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Lymphoma - genetics</subject><subject>Lymphoma - metabolism</subject><subject>Medical prognosis</subject><subject>Models, Biological</subject><subject>Mutation</subject><subject>Neoplasms</subject><subject>Protein Processing, Post-Translational</subject><subject>Proteins</subject><subject>Radiation therapy</subject><subject>Review</subject><subject>Signal transduction</subject><subject>Transcription</subject><subject>Tumors</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpd0ctLAzEQBvAgiq2Pm2dZ8OLB6iTZR_YiaPEFFS_1HLLJbJuym9RkK_S_d7Uq1dME5sdHho-QEwqXnJdwZRdtZBwosIzvkCFNGRsB5MXu1ntADmJcADDOsnKfDHgGIHIBQ3L7aGPnHSbP3tjaatVZ72KinEmmc7Qhmaoww866WWJdMlm3y7m3JnlWjZ055bTFeET2atVEPP6eh-T1_m46fhxNXh6exjeTkU4p60ZYaC50YWpVl6IoeYpCZ0xUqtZciZJVFfawoMYAgkEOWZXr3AgNiLTOkR-S603uclW1aDS6LqhGLoNtVVhLr6z8u3F2Lmf-XYoizVIq-oDz74Dg31YYO9naqLFplEO_ipLlVJSQpynt6dk_uvCr4PrzvhTjJUt5ry42SgcfY8D69zMU5Gc5crucnp9uH_CLf9rgH6GKi_Q</recordid><startdate>20211227</startdate><enddate>20211227</enddate><creator>Fernández-Serrano, Miranda</creator><creator>Winkler, René</creator><creator>Santos, Juliana C</creator><creator>Le Pannérer, Marguerite-Marie</creator><creator>Buschbeck, Marcus</creator><creator>Roué, Gaël</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0245-2257</orcidid><orcidid>https://orcid.org/0000-0002-5779-8805</orcidid><orcidid>https://orcid.org/0000-0001-9040-8496</orcidid><orcidid>https://orcid.org/0000-0002-7570-0242</orcidid><orcidid>https://orcid.org/0000-0003-4148-9570</orcidid><orcidid>https://orcid.org/0000-0002-3218-4567</orcidid></search><sort><creationdate>20211227</creationdate><title>Histone Modifications and Their Targeting in Lymphoid Malignancies</title><author>Fernández-Serrano, Miranda ; Winkler, René ; Santos, Juliana C ; Le Pannérer, Marguerite-Marie ; Buschbeck, Marcus ; Roué, Gaël</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-e7c38c7dfaf987934e8c528bafc3a892bbec4171dd0e0de305b6c6d8c0ee1f6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acetylation</topic><topic>Apoptosis</topic><topic>B-cell lymphoma</topic><topic>Cell cycle</topic><topic>Chemotherapy</topic><topic>Clinical Trials as Topic</topic><topic>DNA damage</topic><topic>DNA methylation</topic><topic>Drug development</topic><topic>Enzymes</topic><topic>Epigenesis, Genetic</topic><topic>Epigenetics</topic><topic>Gene expression</topic><topic>Histones</topic><topic>Histones - metabolism</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immunosuppressive agents</topic><topic>Immunosurveillance</topic><topic>Lymphatic system</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Lymphoma - genetics</topic><topic>Lymphoma - metabolism</topic><topic>Medical prognosis</topic><topic>Models, Biological</topic><topic>Mutation</topic><topic>Neoplasms</topic><topic>Protein Processing, Post-Translational</topic><topic>Proteins</topic><topic>Radiation therapy</topic><topic>Review</topic><topic>Signal transduction</topic><topic>Transcription</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fernández-Serrano, Miranda</creatorcontrib><creatorcontrib>Winkler, René</creatorcontrib><creatorcontrib>Santos, Juliana C</creatorcontrib><creatorcontrib>Le Pannérer, Marguerite-Marie</creatorcontrib><creatorcontrib>Buschbeck, Marcus</creatorcontrib><creatorcontrib>Roué, Gaël</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fernández-Serrano, Miranda</au><au>Winkler, René</au><au>Santos, Juliana C</au><au>Le Pannérer, Marguerite-Marie</au><au>Buschbeck, Marcus</au><au>Roué, Gaël</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histone Modifications and Their Targeting in Lymphoid Malignancies</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2021-12-27</date><risdate>2021</risdate><volume>23</volume><issue>1</issue><spage>253</spage><pages>253-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>In a wide range of lymphoid neoplasms, the process of malignant transformation is associated with somatic mutations in B cells that affect the epigenetic machinery. Consequential alterations in histone modifications contribute to disease-specific changes in the transcriptional program. Affected genes commonly play important roles in cell cycle regulation, apoptosis-inducing signal transduction, and DNA damage response, thus facilitating the emergence of malignant traits that impair immune surveillance and favor the emergence of different B-cell lymphoma subtypes. In the last two decades, the field has made a major effort to develop therapies that target these epigenetic alterations. In this review, we discuss which epigenetic alterations occur in B-cell non-Hodgkin lymphoma. Furthermore, we aim to present in a close to comprehensive manner the current state-of-the-art in the preclinical and clinical development of epigenetic drugs. We focus on therapeutic strategies interfering with histone methylation and acetylation as these are most advanced in being deployed from the bench-to-bedside and have the greatest potential to improve the prognosis of lymphoma patients.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35008680</pmid><doi>10.3390/ijms23010253</doi><orcidid>https://orcid.org/0000-0003-0245-2257</orcidid><orcidid>https://orcid.org/0000-0002-5779-8805</orcidid><orcidid>https://orcid.org/0000-0001-9040-8496</orcidid><orcidid>https://orcid.org/0000-0002-7570-0242</orcidid><orcidid>https://orcid.org/0000-0003-4148-9570</orcidid><orcidid>https://orcid.org/0000-0002-3218-4567</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2021-12, Vol.23 (1), p.253 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8745418 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Acetylation Apoptosis B-cell lymphoma Cell cycle Chemotherapy Clinical Trials as Topic DNA damage DNA methylation Drug development Enzymes Epigenesis, Genetic Epigenetics Gene expression Histones Histones - metabolism Humans Immune system Immunosuppressive agents Immunosurveillance Lymphatic system Lymphocytes B Lymphoma Lymphoma - genetics Lymphoma - metabolism Medical prognosis Models, Biological Mutation Neoplasms Protein Processing, Post-Translational Proteins Radiation therapy Review Signal transduction Transcription Tumors |
| title | Histone Modifications and Their Targeting in Lymphoid Malignancies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T17%3A28%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histone%20Modifications%20and%20Their%20Targeting%20in%20Lymphoid%20Malignancies&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Fern%C3%A1ndez-Serrano,%20Miranda&rft.date=2021-12-27&rft.volume=23&rft.issue=1&rft.spage=253&rft.pages=253-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms23010253&rft_dat=%3Cproquest_pubme%3E2618239243%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2618239243&rft_id=info:pmid/35008680&rfr_iscdi=true |